RU2008136655A - Гибридные белки рецептора vegf, их фармацевтические композиции и терапевтическое применение при заболеваниях глаз - Google Patents

Гибридные белки рецептора vegf, их фармацевтические композиции и терапевтическое применение при заболеваниях глаз Download PDF

Info

Publication number
RU2008136655A
RU2008136655A RU2008136655/13A RU2008136655A RU2008136655A RU 2008136655 A RU2008136655 A RU 2008136655A RU 2008136655/13 A RU2008136655/13 A RU 2008136655/13A RU 2008136655 A RU2008136655 A RU 2008136655A RU 2008136655 A RU2008136655 A RU 2008136655A
Authority
RU
Russia
Prior art keywords
vegf receptor
fusion proteins
angiogenesis
flt
kdr
Prior art date
Application number
RU2008136655/13A
Other languages
English (en)
Russian (ru)
Inventor
Дечао Майкл ЙУ (CN)
Дечао Майкл ЙУ
Original Assignee
Ченгду Кангхонг Биотекнолоджис Ко., Лтд. (Cn)
Ченгду Кангхонг Биотекнолоджис Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ченгду Кангхонг Биотекнолоджис Ко., Лтд. (Cn), Ченгду Кангхонг Биотекнолоджис Ко., Лтд. filed Critical Ченгду Кангхонг Биотекнолоджис Ко., Лтд. (Cn)
Publication of RU2008136655A publication Critical patent/RU2008136655A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
RU2008136655/13A 2006-03-31 2007-03-29 Гибридные белки рецептора vegf, их фармацевтические композиции и терапевтическое применение при заболеваниях глаз RU2008136655A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610066257.2 2006-03-31
CNB2006100662572A CN100502945C (zh) 2006-03-31 2006-03-31 Vegf受体融合蛋白在治疗眼睛疾病中的应用

Publications (1)

Publication Number Publication Date
RU2008136655A true RU2008136655A (ru) 2010-05-10

Family

ID=37736587

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008136655/13A RU2008136655A (ru) 2006-03-31 2007-03-29 Гибридные белки рецептора vegf, их фармацевтические композиции и терапевтическое применение при заболеваниях глаз

Country Status (10)

Country Link
US (1) US20090264358A1 (cg-RX-API-DMAC7.html)
EP (1) EP2000483A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009531036A (cg-RX-API-DMAC7.html)
KR (1) KR20090010030A (cg-RX-API-DMAC7.html)
CN (1) CN100502945C (cg-RX-API-DMAC7.html)
AU (1) AU2007234272A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710223A2 (cg-RX-API-DMAC7.html)
CA (1) CA2647142A1 (cg-RX-API-DMAC7.html)
RU (1) RU2008136655A (cg-RX-API-DMAC7.html)
WO (1) WO2007112675A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
CN101279092B (zh) * 2007-04-02 2010-10-27 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
KR101248912B1 (ko) * 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
CN102233132B (zh) * 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN103816115B (zh) * 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN102380096B (zh) * 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
JP6631865B2 (ja) * 2014-08-11 2020-01-15 日本化薬株式会社 TGFβ阻害機能を持つキメラタンパク質
CN106999511A (zh) 2014-12-11 2017-08-01 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
BR112021003275A2 (pt) 2018-12-07 2021-06-22 Remegen Co., Ltd. inibidor de angiogênese bifuncional e uso do mesmo
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CN115335529B (zh) * 2019-11-26 2026-07-03 马萨诸塞大学 用于递送kh902(康柏西普)的重组腺相关病毒及其用途
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
TW202400214A (zh) 2022-03-15 2024-01-01 美商再生元醫藥公司 用於血管新生眼睛病症之治療之延長高劑量vegf拮抗劑方案
US20230295266A1 (en) 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
EP4588469A4 (en) 2022-09-16 2026-03-04 Qilu Pharmaceutical Co Ltd STABLE, HIGH-CONCENTRATION, SPONTANEOUSLY BUFFERING PHARMACEUTICAL COMPOSITION
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
CN120204358A (zh) * 2023-12-27 2025-06-27 成都康弘生物科技有限公司 一种含有抗vegf的融合蛋白的药物组合物
WO2025217334A1 (en) 2024-04-09 2025-10-16 Regeneron Pharmaceuticals, Inc. Low concentration vegf receptor fusion protein containing formulations
CN118108862B (zh) * 2024-04-29 2024-08-09 上海鼎新基因科技有限公司 抗血管新生的融合蛋白及其应用
KR20260096819A (ko) 2024-12-13 2026-06-24 리제너론 파아마슈티컬스, 인크. 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼
WO2026148214A1 (en) 2025-01-02 2026-07-09 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing buffer free formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AU2004273619A1 (en) * 2003-09-23 2005-03-31 Novartis Ag Combinations of a VEGF receptor inhibitor with other therapeutic agents
CN1304427C (zh) * 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
ES2381014T3 (es) * 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso

Also Published As

Publication number Publication date
AU2007234272A1 (en) 2007-10-11
WO2007112675A8 (fr) 2009-07-09
EP2000483A4 (en) 2009-10-28
CN1915427A (zh) 2007-02-21
EP2000483A9 (en) 2009-03-18
JP2009531036A (ja) 2009-09-03
US20090264358A1 (en) 2009-10-22
CN100502945C (zh) 2009-06-24
CA2647142A1 (en) 2007-10-11
KR20090010030A (ko) 2009-01-28
EP2000483A2 (en) 2008-12-10
WO2007112675A1 (fr) 2007-10-11
BRPI0710223A2 (pt) 2011-08-02

Similar Documents

Publication Publication Date Title
JP2009531036A5 (cg-RX-API-DMAC7.html)
KR101884616B1 (ko) 유착 치료 또는 예방용 폴리펩티드
JP6334061B2 (ja) 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法
RU2012148887A (ru) Варианты дезинтегрина и их фармацевтическое применение
JPH02501028A (ja) トロンビンから誘導されたポリペプチド、組成物およびその使用方法
JP2009531036A (ja) Vegf受容体融合タンパク質およびそれらの使用
JP2020528742A5 (cg-RX-API-DMAC7.html)
CN101605555A (zh) 用于治疗伤口的基于TGF-β单体的药物和蛋白质
RU2010135532A (ru) Лечение и предупреждение болезней сердца с использованием двух или более изоформ фактора роста гепатоцидов
KR20200078425A (ko) 재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도
CA2703614A1 (en) Splice variants of gdnf and uses thereof
TW200829267A (en) Method of treating endothelial dysfunction
WO2016019036A2 (en) Recombinant collagen iv surrogates and uses thereof
EP2599788B1 (en) Angiogenesis-inhibiting peptide and application thereof
WO2000010608A1 (en) Preventives/remedies for arteriosclerosis and post-ptca reangiostenosis
Kim et al. Newly designed Protein Transduction Domain (PTD)‐mediated BMP‐7 is a potential therapeutic for peritoneal fibrosis
CN113755580A (zh) 一种治疗和/或缓解淋巴水肿的药物干预靶点及其应用
Sun et al. Subconjunctival conbercept for the treatment of corneal neovascularization
CN102241776B (zh) Rankl-tnf样区融合蛋白及其制备方法和应用
CA2356009A1 (en) Vascular endothelial growth factor-x
Wang et al. A novel small PEPTIDE H-KI20 inhibits retinal neovascularization through the JNK/ATF2 signaling pathway
CN100484957C (zh) 胸腺素β4衍生物及其应用
WO2012013110A1 (zh) 具有抑制血管生成活性的多肽
KR20100075471A (ko) 트롬빈 유래 펩타이드를 포함하는 망막증 또는 녹내장 치료용 조성물
CN103205410B (zh) 重组微纤维蛋白溶酶及其制备方法和应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110610